Literature DB >> 24513476

Impact of the angiographic mechanisms underlying periprocedural myocardial infarction after drug-eluting stent implantation.

Duk-Woo Park1, Young-Hak Kim1, Sung-Cheol Yun2, Jung-Min Ahn1, Jong-Young Lee1, Won-Jang Kim1, Soo-Jin Kang1, Seung-Whan Lee1, Cheol Whan Lee1, Seong-Wook Park1, Seung-Jung Park3.   

Abstract

Periprocedural myocardial infarction (MI) can be induced by several angiographic mechanisms. However, there are limited data on whether these mechanisms differentially affect clinical outcomes. The purpose of our study was to investigate the impact of periprocedural MI on mortality according to the underlying angiographic mechanisms after drug-eluting stent (DES) implantation. We pooled the databases from 7 coronary stent trials using DES. Periprocedural MI was classified according to its underlying angiographic mechanisms as type 1 (due to side-branch occlusion), type 2 (due to other angiographic complications), or type 3 (without angiographically identifiable causes). Among 10,889 patients treated with DES, 768 (7.1%) experienced periprocedural MI; 463 cases (60.3%) were driven by type 1 cause, 138 (18.0%) by type 2 cause, and 167 (21.7%) by type 3 cause. Mortality rates at 2 years were higher in patients with periprocedural MI than in those without (3.5% vs 2.1%, respectively). Significant differences in mortality were observed according to the angiographic mechanisms of MI (type 1: 2.8% vs type 2: 6.1% vs type 3: 3.1%). After multivariable adjustment, type 2 MI was significantly associated with an increased risk of mortality (hazard ratio 2.65, 95% confidence interval 1.77 to 3.96), whereas type 1 and type 3 MI were not related with increased mortality. In conclusion, among patients receiving DES implantation, periprocedural MI was associated with increased mortality, and there were differential associations with mortality according to the underlying angiographic mechanisms.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24513476     DOI: 10.1016/j.amjcard.2013.12.016

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial.

Authors:  Liefke C van der Heijden; Marlies M Kok; Ming Kai Lam; Peter W Danse; Alexander R Schramm; Gillian A J Jessurun; R Melvyn Tjon Joe Gin; K Gert van Houwelingen; Raymond W M Hautvast; Gerard C M Linssen; Hanim Sen; Marije M Löwik; Maarten J IJzerman; Carine J M Doggen; Clemens von Birgelen
Journal:  Clin Res Cardiol       Date:  2015-09-02       Impact factor: 5.460

2.  Predictive value of baseline C-reactive protein for periprocedural myocardial infraction of higher risk stratifications: A retrospective cohort clinical study.

Authors:  Mingyang Yao; Linlin Zhao; Lili Wu; Wenbin Zhang; Yi Luan; Jiale Song; Guosheng Fu; Junhui Zhu
Journal:  Anatol J Cardiol       Date:  2018-09-17       Impact factor: 1.596

3.  Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial.

Authors:  Gregg W Stone; Philippe Généreux; Robert A Harrington; Harvey D White; C Michael Gibson; P Gabriel Steg; Christian W Hamm; Kenneth W Mahaffey; Matthew J Price; Jayne Prats; Efthymios N Deliargyris; Deepak L Bhatt
Journal:  Eur Heart J       Date:  2018-12-07       Impact factor: 29.983

4.  Myocardial damage associated with elective percutaneous coronary intervention in Chinese patients: a retrospective study.

Authors:  Shengjia Sun; Yang Ou; Haiming Shi; Jianfeng Luo; Xinping Luo; Yunzhi Shen; Yufei Chen; Xiaojin Liu; Zhidong Zhu; Wei Shen
Journal:  J Int Med Res       Date:  2020-03       Impact factor: 1.671

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.